Clinical Trials Listing Service

CASCADE FH Registry: Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia

Last updated: June 19, 2017
Sponsor: The FH Foundation
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

TX150277
  • All Genders

Study Summary

CASCADE FH Registry: Cascade Screening for Awareness and Detection of Familial Hypercholesterolemia

Eligibility Criteria

Inclusion

Potential candidates are males or females, with an existing clinical diagnosis of FH, which is generally characterized by a pre-treatment (no lipid lowering medication) LDL-C level > 190 mg/dL, or total cholesterol level > 300 mg/dL. Potential candidates that are receiving treatment (on lipid lowering medication) with a diagnosis of FH are generally characterized by having an LDL-C level >124 mg/dL or total cholesterol level > 195 mg/dL.

Study Design

Study Start date:
June 19, 2017
Estimated Completion Date:

Study Description

The purpose of this registry is to collect and maintain clinical information about patients that have been diagnosed with Familial Hypercholesterolemia (FH). The information will be used to look at current treatment, events, and outcomes of these patients. This will help further the understanding of the disease and improve care, quality of life, and survival of patients with FH.

FH is a common genetic condition that occurs in approximately 1 in 300-500 individuals. FH is characterized by a dramatically high level of LDL-C, which is not related to diet or lifestyle. Because of a life long burden of high cholesterol levels, young individuals with FH have a greater risk of coronary disease compared to the general population. FH is genetically inherited, and if one person is diagnosed with FH, his/her family members should also be screened.

By participating in the CASCADE Registry, the study staff will have access to the participants’ medical records. The study staff will collect information such as the medical history, procedures, laboratory results, and current medications from the participants’ medical records. There is no limit on the length of time participants will be in the study; participants will be in the registry as long as it remains open, or the participant decides to stop taking part of the registry.

There is no guarantee that participants will receive direct benefit from this study. However, participation in this study may help others get a better treatment for their FH in the future, and allow researchers to learn more about the management of FH and promote awareness for FH.

For more information, please contact:
Nelson Chen, CRC
646-317-0785
nec9039@nyp.org

Connect with a study center

  • The Rogosin Institute

    New York, New York 10021
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.